Physician profile
Jeffrey E Baumel
NPI 1285658450
$2,287.64
in general payments reported to CMS, 2019-2025
9 companies · $248 in 2025
The $248 reported for 2025 was more than what 84% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $169 · 2021: $601 · 2022: $358 · 2023: $341 · 2024: $266 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Education: $37.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.62 |
| Education | $37.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $1,275.72 | 2019-2025 | Caldolor, Vibativ |
| Merck Sharp & Dohme LLC | $496.58 | 2019-2025 | Bridion, Verquvo |
| Biotronik INC. | $141.84 | 2021 | |
| Chiesi USA, INC. | $133.18 | 2019-2025 | Cleviprex, Kengreal |
| E.R. Squibb & Sons, L.L.C. | $116.87 | 2021 | |
| Eagle Pharmaceuticals, INC. | $51.78 | 2023-2024 | |
| Heron Therapeutics, INC. | $33.44 | 2025 | Aponvie |
| Janssen Pharmaceuticals, INC | $19.48 | 2019 | |
| Vifor Pharma, INC. | $18.75 | 2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Baumel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.